GR agonists(Glucocorticoid receptor agonists), cPLA2α agonists(Cytosolic phospholipase A2 agonists), β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesRespiratory Diseases

Active Indication

Airway ObstructionBronchitis, ChronicPulmonary Emphysema+ [2]

Inactive Indication

airway diseaseBronchiolitis ObliteransEmphysema+ [2]

Originator Organization

GSK Plc

Active Organization

Hangzhou Chance Pharmaceuticals Co., Ltd.

GSK PlcTeva Pharmaceuticals Europe BV

+ [10]

Inactive Organization

Teva Branded Pharmaceutical Products R&D, Inc.Mylan Pharma UK Ltd.

Drug Highest PhaseApproved

First Approval Date

United States (24 Aug 2000),

AsthmaPulmonary Disease, Chronic Obstructive

Regulation-

Structure/Sequence

Molecular FormulaC25H31F3O5S

InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N

CAS Registry80474-14-2

View All Structures (2)

269

Clinical Trials associated with Fluticasone propionate/Salmeterol xinafoate

CTR20244821

/ RecruitingNot Applicable

沙美特罗替卡松粉吸入剂在健康人空腹状态下的生物等效性试验

[Translation] Bioequivalence study of salmeterol-fluticasone powder for inhalation in healthy volunteers under fasting condition

主要研究目的本试验目的是以正大天晴药业集团股份有限公司研制并生产的沙美特罗替卡松吸入粉雾剂为受试制剂，按有关生物等效性试验的规定，与Glaxo Wellcome Production生产的沙美特罗替卡松吸入粉雾剂（参比制剂，商品名：舒利迭®）进行人体生物等效性试验。次要研究目的观察受试制剂沙美特罗替卡松吸入粉雾剂和参比制剂沙美特罗替卡松吸入粉雾剂（舒利迭®）在健康人中的安全性。

[Translation]

Main research purpose The purpose of this study is to use the salmeterol/fluticasone inhalation powder developed and produced by Zhengda Tianqing Pharmaceutical Group Co., Ltd. as the test preparation, and conduct a human bioequivalence study with the salmeterol/fluticasone inhalation powder produced by Glaxo Wellcome Production (reference preparation, trade name: Seretide®) according to the relevant provisions of the bioequivalence test. Secondary research purpose Observe the safety of the test preparation salmeterol/fluticasone inhalation powder and the reference preparation salmeterol/fluticasone inhalation powder (Seretide®) in healthy people.

Start Date28 Dec 2024

Sponsor / Collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

CTR20244110

/ CompletedNot Applicable

沙美特罗替卡松吸入粉雾剂在中国成年健康受试者中的一项单中心、随机、开放、空腹单次给药生物等效性试验

[Translation] A single-center, randomized, open-label, fasting single-dose bioequivalence study of salmeterol/fluticasone inhalation powder in healthy Chinese adult subjects

主要研究目的：考察空腹状态下单次经口吸入受试制剂沙美特罗替卡松吸入粉雾剂与参比制剂沙美特罗替卡松吸入粉雾剂在中国健康人体的相对生物利用度，比较两制剂药代动力学特征，评估两制剂的生物等效性。次要研究目的：评价空腹状态下使用受试制剂和参比制剂在中国成年健康受试者中的安全性。

[Translation]

The main purpose of the study is to investigate the relative bioavailability of the test preparation salmeterol-fluticasone inhalation powder and the reference preparation salmeterol-fluticasone inhalation powder in healthy Chinese subjects after single oral inhalation in the fasting state, to compare the pharmacokinetic characteristics of the two preparations, and to evaluate the bioequivalence of the two preparations. Secondary purpose of the study is to evaluate the safety of the test preparation and the reference preparation in healthy Chinese adult subjects in the fasting state.

Start Date07 Nov 2024

Sponsor / Collaborator

Aitme (Suzhou) Medical Technology Co., Ltd.

NCT06676319

/ RecruitingPhase 2

A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment

This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma.
The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig compared with placebo in male and female participants (aged 18 to 80 years, inclusive) with asthma, who are not currently eligible for biologic treatments.
Study details include:
* The study duration will be approximately 64 weeks for participants not transitioning into the LTS study and approximately 60 weeks for participants transitioning into the LTS study.
* The investigational treatment duration will be up to approximately 52 weeks.
* The number of visits will be 18.

Start Date07 Nov 2024

Sponsor / Collaborator

Sanofi

100 Clinical Results associated with Fluticasone propionate/Salmeterol xinafoate

100 Translational Medicine associated with Fluticasone propionate/Salmeterol xinafoate

100 Patents (Medical) associated with Fluticasone propionate/Salmeterol xinafoate

630

Literatures (Medical) associated with Fluticasone propionate/Salmeterol xinafoate

01 Mar 2025·TROPICAL ANIMAL HEALTH AND PRODUCTION

Effects of sunflower cake in lamb diets on meat quality and its fatty acid profile

Article

Author: da Silva, Luciana Kimie Savay ; da Costa, Dorival Pereira Borges ; da Costa, Ana Cláudia ; de Oliveira Roça, Roberto ; de Mattos Negrão, Fagton ; Rodrigues, Deivison Novaes ; Zervodakis, Joanis Tilemahos ; da Costa, Quezia Pereira Borges ; Fonseca, Alessandra Schaphauser Rosseto ; de Abreu, Matheus Lima Corrêa ; de Paula, Nelcino Francisco ; da Silva Cabral, Luciano

This study aimed to evaluate the effects of sunflower cake (SFC) levels (0, 7, 14, 21, and 28% dry matter) in the diet for feedlot lambs on meat quality and its fatty acid profile. Forty crossbreed non castrated hair lambs were fed with experimental diets through 70 days when they were slaughtered and a Longissimus lumborum section were evaluated for physicochemical quality and fatty acid profile. There were no effects of SFC levels (P > 0.05) on chemical composition of meat, except on moisture (P < 0.05) which was quadratically affected by SFC. The fat thickness (EG) was quadratically affected by SFC level (P < 0.05), but cooking losses, meat pH, shear force, loin eye area were not affected by SFC. The saturated fatty acids (SFA), monounsaturated fatty acids (MUFA), total of unsaturated fatty acids (TUFA) and MUFA:SFA ratio were not affected by the inclusion of SFC (P < 0.05), however, polyunsaturated fatty acids (PUFA) and PUFA:SFA ratio increased linearly (P < 0.05) while saturated hypercholesterolemic (SHC) were quadratically affected (P < 0.05). The SFC promoted a linear decrease on palmitoleic acid in the meat whereas linoleic, cis-9, trans-11 CLA and trans-10, cis-12 CLA were linearly increased (P < 0.05). Taken together, these data suggest that SFC fed up 28% on dry matter basis in lamb diets do not cause negative effects on meat quality and still promote improvement on its quality in health perspective by increasing CLA content.

01 Mar 2025·INTERNATIONAL IMMUNOPHARMACOLOGY

5-aminolaevulinic acid with sodium ferrous citrate alleviated kidney injury and fibrosis in a unilateral ureteral obstruction model

Article

Author: Ito, Hidenori ; Nakajima, Motowo ; Takahashi, Kiwamu ; Hu, Xin ; Ding, Zhaolun ; Fujino, Masayuki ; Yang, Yang ; Ma, Kuai ; Li, Xiao-Kang ; Isaka, Yoshitaka

PURPOSE:

This study aimed to investigate the potential therapeutic effects of 5-aminolaevulinic acid (5-ALA) combined with sodium ferrous citrate (SFC) on kidney injury and fibrosis in a mouse model of unilateral ureteral obstruction (UUO)-induced chronic kidney disease (CKD).

METHODS:

A murine UUO model was used to mimic human CKD. The mice received daily intragastric administration of 5-ALA/SFC for 7 and 14 consecutive days. Serum creatinine (Cr) and blood urea nitrogen (BUN) levels and histological evaluations were performed to assess the renal function parameters underlying 5-ALA/SFC treatment in the UUO model. Differentially expressed genes (DEGs) were analyzed by RNA sequencing (RNA-Seq), and the results were validated by quantitative real-time PCR (qRT-PCR). The severity of renal fibrosis was evaluated using Sirius red and Masson's trichrome (MT) staining techniques, while the expression of fibrosis-related genes was examined using western blotting and immunohistochemistry.

RESULTS:

Our findings demonstrated that 5-ALA/SFC treatment improved UUO-induced renal dysfunction, attenuated tubular damage, and significantly reduced serum Cr and BUN levels as well as the mRNA expression and secretion of pro-inflammatory and programmed cell death-related cytokines in kidney tissues. Furthermore, 5-ALA/SFC suppressed renal tissue fibrosis and downregulated the mRNA and protein expression of fibrosis-related genes. Notably, treatment with 5-ALA/SFC led to the significant upregulation of protein expression levels of PPAR gamma-coactivator-1α (PGC-1α), indicating its role in inhibiting inflammation and fibrosis through the activation of the PGC-1α signaling pathway.

CONCLUSION:

5-ALA/SFC exhibits renoprotective effects in UUO-induced CKD by attenuating inflammation, cell death, and suppressing renal fibrosis. These findings suggest a specific renal protective mechanism for 5-ALA/SFC, highlighting its potential as a novel therapeutic agent for human CKD treatment.

01 Jan 2025·EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

A weekly 4‐methylpyrazole treatment attenuates the development of non‐obese metabolic dysfunction‐associated steatotic liver disease (MASLD) in male mice: Role of JNK

Article

Author: Baumann, Anja ; Jung, Finn ; Bergheim, Ina ; Kopp, Florian ; Brandt, Annette ; Schweiger, Kerstin ; Staltner, Raphaela ; Csarmann, Katja ; Burger, Katharina ; Scholda, Julia

Abstract:

Background:

4‐methylpyrazole (4MP, fomepizole) is a competitive inhibitor of alcohol dehydrogenase (ADH) preventing the metabolism of ethylene glycol and methanol, respectively, into their toxic metabolites. 4MP seems also to possess a potential in the treatment of intoxication from other substance, for example, acetaminophen, and to modulate JNK‐dependent signalling. Here, we determined if a treatment with 4MP once weekly affects the development of diet‐induced non‐obese metabolic dysfunction‐associated steatotic liver disease (MASLD) in C57BL/6 mice.

Methods:

Male C57BL/6 mice (6–8 weeks old, n = 7‐8/group) were pair‐fed either a liquid control diet (C) or a liquid sucrose‐, fat‐ and cholesterol‐rich diet (SFC) for 8 weeks while being concomitantly treated with 4MP (50 mg/kg bw i.p.) or vehicle once a week. Liver damage, inflammatory markers and glucose tolerance were assessed. Moreover, in endotoxin‐challenged J774A.1 cells pretreated with 4MP, pro‐inflammatory markers were assessed.

Results:

The concomitant treatment of SFC‐fed mice with 4MP attenuated the increase in JNK phosphorylation and pro‐inflammatory markers like IFNγ, IL‐6 and 3‐nitrotyrosine protein adducts in liver tissue found in vehicle‐treated SFC‐fed mice, while not affecting impairments of glucose tolerance or the increase in portal endotoxin levels. Moreover, a pretreatment of endotoxin‐stimulated J774A.1 cells with 4MP significantly attenuated the increases in JNK phosphorylation and pro‐inflammatory mediators like IL‐6 and Mcp1.

Conclusions:

Taken together, our results suggest that a treatment with 4MP once weekly attenuates the activation of JNK and dampens the development of non‐obese MASLD in mice.

News (Medical) associated with Fluticasone propionate/Salmeterol xinafoate

12 Nov 2024

·www.prnewswire.com

Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight

After over a decade without notable progress in treating chronic obstructive pulmonary disease, patients with this ongoing condition now have two new treatment options, with more expected in the future. Regeneron and Sanofi recently revealed that the FDA has expanded the approved uses of their widely successful drug DUPIXENT to include COPD treatment. This marks the drug's sixth approved indication in the US, following its first approval seven years ago for atopic dermatitis. LAS VEGAS, Nov. 12, 2024 /PRNewswire/ -- Chronic obstructive pulmonary disease (COPD) is a progressive lung condition characterized by obstructed airflow, making breathing difficult. It primarily encompasses two main conditions: chronic bronchitis and emphysema, often coexisting. COPD typically develops due to long-term exposure to irritants such as cigarette smoke, air pollution, or occupational dust. As per DelveInsight analysis, the diagnosed prevalent population of COPD in the 7MM was around 44 million in 2023. These cases of COPD in the 7MM are expected to increase at a significant CAGR of 1.4% throughout the study period (2020–2034). As per the estimates, the majority of cases of COPD are in females as compared to males, in the US. But in EU4 and the UK, and Japan the diagnosed cases of males represent the majority of the cases. Overall, in the 7MM, females are predominantly high in number. In 2023, the US had around 3 million, 9 million, 5 million, and 1 million cases of GOLD 1, GOLD 2, GOLD 3, and GOLD 4, respectively based on the severity of airflow limitation. Estimates suggest that airflow limitation was higher in GOLD 2 severity. Various types of medications are used to manage COPD symptoms and complications, including bronchodilators, which help relax the muscles around the airways. This relaxation opens the airways and makes breathing easier. Most bronchodilators are administered via an inhaler. In more severe cases, the inhaler may also contain steroids to reduce inflammation. Some commonly used short-acting and long-acting bronchodilators for COPD management include Albuterol (ProAir HFA, Ventolin HFA, and others), Ipratropium (Atrovent HFA), Levalbuterol (Xopenex), Aclidinium (Tudorza Pressair), Arformoterol (Brovana), and Formoterol (Perforomist). In the LABA category, medications such as Striverdi Respimat, Arcapta/Onbrez, Serevent, and Brovana are included, while the LAMA class features drugs like Spiriva (available as Spiriva HandiHaler and Spiriva Respimat), Tudorza Pressair, Incruse Ellipta, Yupelri, Seebri Neohaler, and Lonhala Magnair. Since the generic version of Brovana was approved in April 2020, its market share has declined. Additionally, Arcapta Neohaler, Seebri Neohaler, and Utibron Neohaler were discontinued in the US in March 2020, which means they no longer contribute to market size. Patients who do not respond to single therapies are often prescribed double or triple therapy. Among the double therapies, the LABA+ICS combination is widely recommended, with drugs such as Symbicort, Breo Ellipta, and Advair. There are also LABA+LAMA combinations, including Anoro Ellipta, Stiolto Respimat, and Bevespi Aerosphere. In July 2020, the US FDA approved AstraZeneca's BREZTRI AEROSPHERE for the maintenance treatment of patients with COPD. Additionally, in October 2020, TRIXEO AEROSPHERE (a combination of formoterol fumarate, glycopyrronium bromide, and budesonide) received marketing authorization in the EU for the maintenance treatment of adult patients with moderate to severe COPD who are not adequately controlled by either a combination of an ICS and LABA or a LABA and LAMA. Currently, two triple combination therapies are available in the US: BREZTRI and TRELEGY ELLIPTA. Learn more about the FDA-approved COPD drugs @ Drugs for COPD Treatment Recently, Sanofi/Regeneron Pharmaceuticals' DUPIXENT added one more jewel to its crown by getting a label expansion nod for COPD from the FDA, EU, and NMPA. DUPIXENT's approval as the first targeted therapy for COPD represents a significant advancement in the treatment landscape for the disease. Unlike conventional treatments, which largely aim to manage symptoms, DUPIXENT specifically targets the IL-4 and IL-13 pathways linked to type 2 inflammation, a key driver in a subset of COPD patients. This precision in targeting allows for a more tailored treatment, especially for patients with elevated eosinophils, who often experience more frequent exacerbations and worse outcomes. The Phase III BOREAS trial demonstrated that patients treated with DUPIXENT experienced a 30% reduction in moderate-to-severe exacerbations over 52 weeks, significant improvements in lung function, and enhanced quality of life. By Week 52, those on DUPIXENT had improved prebronchodilator FEV1 by 160 mL compared to 77 mL in the placebo group. DUPIXENT was also well-tolerated, with a low frequency of adverse events. These results suggest that DUPIXENT could drastically shift COPD management by reducing exacerbations, improving lung function, and offering a safer, targeted therapy for patients with type 2 inflammation. To know more about COPD treatment options, visit @ New Treatment for COPD The chronic obstructive pulmonary disease pipeline possesses potential drugs in mid-stage developments to be launched in the near future. Itepekimab (Sanofi/Regeneron Pharmaceuticals), Benralizumab (AstraZeneca), Tezepelumab (Amgen/AstraZeneca), Mepolizumab (GSK), and others shall further create a positive impact on the market. Discover which therapies are expected to grab major COPD market share @ COPD Market Report Itepekimab is a fully human monoclonal antibody that targets interleukin-33 (IL-33), a protein involved in both type 1 and type 2 inflammation. The drug is administered via subcutaneous injection. Preclinical studies demonstrated that REGN3500 effectively inhibited several markers of both inflammatory types. Regeneron and Sanofi are investigating REGN3500 in diseases related to respiratory and dermatological inflammation. Currently, REGN3500 is in a Phase III clinical trial for COPD and was developed using Regeneron's VelocImmune technology, which produces optimized fully human antibodies. The development is part of a global collaboration between Regeneron and Sanofi. FASENRA (benralizumab) is a humanized recombinant monoclonal antibody of the IgG1k immunoglobulin type that selectively targets the alpha chain of the interleukin 5 receptor (IL-5R) found on eosinophils and basophils. It prevents IL-5 from binding and stops the hetero-oligomerization of the IL-5R's alpha and beta subunits, thereby inhibiting signal transduction. Additionally, it is an afucosylated IgG, which enhances its affinity for the FcγRIIIα receptor on natural killer cells, macrophages, and neutrophils. Approved by the FDA in November 2017 for severe eosinophilic asthma, benralizumab was developed by MedImmune, AstraZeneca's global biologics R&D division. The company is currently conducting Phase III clinical trials for FASENRA as a treatment for COPD. TEZSPIRE (tezepelumab), a pioneering human monoclonal antibody created by Amgen and AstraZeneca, has shown considerable therapeutic potential for various respiratory conditions. Originally intended for treating COPD, TEZSPIRE has yielded encouraging results in decreasing moderate-to-severe exacerbations in patients with high blood eosinophil counts. Recent findings from the Phase IIa COURSE Trial, unveiled at the ATS 2024 conference, underscored TEZSPIRE's effectiveness in minimizing COPD exacerbations among patients with different eosinophil levels. Mepolizumab is currently undergoing Phase III clinical trials for COPD, particularly in patients with frequent exacerbations and elevated eosinophil levels. It is available as an injectable solution and a powder for reconstitution for subcutaneous administration. The IL-5 receptor complex activates several signaling pathways that lead to the release of cytokines, neuromediators, chemokines, and various kinases, which facilitate eosinophil differentiation, proliferation, recruitment, and degranulation. Mepolizumab works by inhibiting the formation of the IL-5 receptor complex, thereby preventing eosinophil activation. This disruption affects normal eosinophil maturation and function, leading to decreased eosinophilic airway inflammation and reduced eosinophil survival. Discover more about drugs for COPD in development @ COPD Clinical Trials The anticipated launch of these emerging therapies for COPD are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the COPD market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for COPD in the 7MM is expected to grow from USD 16 billion in 2023 with a significant CAGR of 5% by 2034. This growth is mainly driven by the rise in the number of prevalent cases of COPD, ongoing clinical research, and better diagnostic tools that might improve the prognosis of the disease. DelveInsight's latest published market report titled as Chronic Obstructive Pulmonary Disease Market Insight, Epidemiology, and Market Forecast – 2034 will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the COPD country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The COPD market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Diagnosed Prevalent Cases of COPD Subtype-specific Diagnosed Prevalent Cases of COPD Gender-specific Diagnosed Prevalent Cases of COPD Age-specific Diagnosed Prevalent Cases of COPD Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM COPD market. Highlights include: 11-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this COPD market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the COPD market. Also, stay abreast of the mitigating factors to improve your market position in the COPD therapeutic space. Related Reports Chronic Obstructive Pulmonary Disease Pipeline Chronic Obstructive Pulmonary Disease Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key COPD companies, including Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma plc, Immunotek, Yungjin Pharm. Co., Ltd., Pulmotect, Inc., Tetherex Pharmaceutical, CSL Behring, AstraZeneca, Novartis, Genentech, Vertex Pharmaceuticals, EmeraMed, Afimmune, Mereo BioPharma, Synairgen, Adamis Pharmaceuticals, Quercegen Pharmaceuticals LLC, Regend Therapeutics, Meridigen Biotech Co., Ltd., Pulmatrix, Eisai, GlaxoSmithKline, EpiEndo Pharmaceuticals, 3SBio, OmniSpirant, Foresee Pharmaceuticals, Amgen, Organicell Regenerative Medicine, Arrowhead Pharmaceuticals, ProterixBio, RS BioTherapeutics, MitoRx, C4X Discovery, Respiratorius, ARK biosciences, Incannex, GNI Pharma, Celon pharma, Alveolus Bio, Kinaset therapeutics, Landos Biopharma, Parion Sciences, KeyMed Biosciences, Bioneer corporation, AlgiPharma, Palobiofarma, Dimerix Bioscience, Glenmark Pharmaceuticals, among others. Asthma Market Asthma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key asthma companies including GlaxoSmithKline, 4D Pharma plc, AstraZeneca, Suzhou Connect Biopharmaceuticals, Avillion, Pearl Therapeutics, ARS Pharmaceuticals, Sinomab, Avalo Therapeutics, Kymab, Sanofi, Cumberland Pharmaceuticals, Genentech, Inc. , among others. Asthma Pipeline Asthma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key asthma companies, including Jiangsu Hengrui Medicine, GlaxoSmithKline, Immunotek SL, AB Science, EMS, Avalo Therapeutics, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., ARS Pharmaceuticals, Sanofi, Zura Bio Ltd., AstraZeneca, EURRUS Biotech GmbH, T-Balance Therapeutics GmbH, Gossamer Bio, Aldeyra Therapeutics, Inc., Trio Medicines, Janssen Research & Development, Arrowhead Pharmaceuticals, Hoffman-La-Roche, GlaxoSmithKline, Biohaven Pharmaceutical, TAK-Circulator Co., Shanghai Hengrui Pharmaceutical, among others. Acute Respiratory Distress Syndrome Market Acute Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ARDS companies, including MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, APEPTICO Forschung und Entwicklung GmbH, Staidson (Beijing) Biopharmaceuticals, Veru, Mesoblast Limited, Avalo Therapeutics, Pluristem Therapeutics, ILTOO Pharma, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultDrug ApprovalPhase 3Phase 2

30 Jul 2024

·www.fiercepharma.com

South Korea regulator hits GSK for problems with asthma, acne drugs: report

South Korea’s Ministry of Food and Drug Safety penalized GSK for failing to inform the agency of a change in API specifications in certain asthma meds. South Korea’s Ministry of Food and Drug Safety issued a pair of administrative penalties to GSK for manufacturing and labeling problems on certain asthma and acne treatments, Korea Biomedical Review reports.In its rebuke of GSK, the regulatory agency said the company violated regulations by failing to report changes it made to the APIs used to make Seretide 100 Discus (fluticasone-salmeterol), Seretide 250 Discus, Seretide 500 Discus, and Flixotide Junior Evohaler 50, according to KBR. The drugs are used to treat asthma.The company was also scolded for confusing manufacturing numbers and expiration dates on its labels for acne drug Duacgel 5% (clindamycin phosphate-containing benzoyl peroxide), according to the publication. As part of its action, the agency imposed a 15-day sales suspension from Aug. 1 to 15 on Duacgel 5%, according to KBR.GSK was fined 52.2 million won ($37,680) on Seretide 100 Discus, Seretide 250 Discus, and Seretide 500 Discus. GSK was also hit with a six-month import suspension on Flixotide Junior Evohaler 50mcg that runs from Aug. 1, 2024, to Jan. 31, 2025.Fierce reached out to GSK for comment on the regulatory action.

Drug Approval

08 Aug 2023

·www.drugs.com

Generic, Brand-Name Medication Similarly Effective for COPD

MONDAY, Aug. 7, 2023 -- For patients with chronic obstructive pulmonary disease (COPD), generic and brand-name fluticasone-salmeterol are similarly effective and safe, according to a study published online Aug. 8 in the Annals of Internal Medicine . William B. Feldman, M.D., D.Phil., from Brigham and Women's Hospital in Boston, and colleagues compared the effectiveness and safety of generic (Wixela Inhub) and brand-name (Advair Diskus) fluticasone-salmeterol among patients with COPD in a propensity score-matched cohort study. Of 27,305 Advair Diskus users and 18,064 Wixela Inhub users, 10,012 matched pairs were included in the primary analysis. The researchers found that Wixela Inhub use was associated with a nearly identical incidence of first moderate or severe COPD exacerbation compared with Advair Diskus (hazard ratio, 0.97; 95 percent confidence interval, 0.90 to 1.04) and with a similar incidence of first pneumonia hospitalization (hazard ratio, 0.99; 95 percent confidence interval, 0.86 to 1.15). "In patients with COPD, the generic inhaled corticosteroid-long-acting β-agonist Wixela Inhub had nearly identical effectiveness and safety when compared with brand-name Advair Diskus," the authors write. "Similar studies can provide a useful means of evaluating the clinical effectiveness and safety of complex generic products after approval." Abstract/Full Text (subscription or payment may be required) Posted August 2023

Clinical Result

100 Deals associated with Fluticasone propionate/Salmeterol xinafoate

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	R03AK06	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Airway Obstruction	United States	Glaxo Group Ltd.	30 Apr 2008
Bronchitis, Chronic	Japan	GlaxoSmithKline KK	18 Apr 2007
Pulmonary Emphysema	Japan	GlaxoSmithKline KK	18 Apr 2007
Asthma	United States	Glaxo Group Ltd.	24 Aug 2000
Pulmonary Disease, Chronic Obstructive	United States	Glaxo Group Ltd.	24 Aug 2000

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bronchiolitis Obliterans	Phase 3	France	GSK Plc	21 May 2021
Persistent asthma	Phase 3	United States	GSK Plc	01 Feb 2007
Persistent asthma	Phase 3	Australia	GSK Plc	01 Feb 2007
Persistent asthma	Phase 3	Canada	GSK Plc	01 Feb 2007
Persistent asthma	Phase 3	Chile	GSK Plc	01 Feb 2007
Persistent asthma	Phase 3	Costa Rica	GSK Plc	01 Feb 2007
Persistent asthma	Phase 3	Germany	GSK Plc	01 Feb 2007
Persistent asthma	Phase 3	Latvia	GSK Plc	01 Feb 2007
Persistent asthma	Phase 3	Lithuania	GSK Plc	01 Feb 2007
Persistent asthma	Phase 3	Mexico	GSK Plc	01 Feb 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04677959 (CONNECT2, CTgov)	Phase 4	Asthma	427	Albuterol+Fluticasone propionate/salmeterol (FS)	svcivpzlua = zivhkkkmhw vmjexzzzpj (armgblxlxy, sjwcuvvwtk - ionrscwfai) View more	-	14 Mar 2023
ERS2022	Not Applicable	Pulmonary Disease, Chronic Obstructive Maintenance	195	Budesonide/Formoterol MART	xcvcgshduh(vhcgbbfdev) = Similar proportions of patients reported adverse events (Budesonide/Formoterol MART: 73% vs Fluticasone/Salmeterol fixed-dose therapy: 68%, p=0.41) jcvtlezozo (xmrgqzpjtw ) View more	-	04 Sep 2022
				Fluticasone/Salmeterol fixed-dose therapy
NCT02571777 \| NCT02554786 (PALLADIUM and IRIDIUM, Pubmed \| BMJ Open Respir Res)	Phase 3	Asthma	3,154	Mometasone furoate/indacaterol acetate (high-dose)	napvgoixoi(gpidhflrzh) = psqomnizlx ykurrjguzo (xbctvgtzjv ) View more	Positive	01 Aug 2021
				Fluticasone propionate/salmeterol xinafoate (high-dose)	hmpjabmzkk(hxrmegjbrx) = ntqebkqaxg ysbfxgcfcw (clviiyjsfz )
NCT03219866 (CTgov)	Phase 4	Pulmonary Disease, Chronic Obstructive \| Disease Progression	40	Nebulizers+Pulmicort+Brovana+Atrovent (Nebulizers)	uffxfcordw(qazredlhnz) = tvfxkjdmyj zbqqvqnlgf (pzaqhomopo, 25.2) View more	-	10 Jun 2021
				Dry Powder Inhaler+Spiriva HandiHaler+Advair Diskus (Dry Powder Inhaler)	uffxfcordw(qazredlhnz) = jiyfhqgsue zbqqvqnlgf (pzaqhomopo, 19.8) View more
NCT02245672 (Pubmed \| J Aerosol Med Pulm Drug Deliv)	Phase 3	Asthma	1,127	Wixela Inhub	esygnqprwa(umifibhoyz) = qprexqnbhg jnkqxyipox (swwhrkdpey ) View more	-	01 Apr 2020
				Advair Diskus	esygnqprwa(umifibhoyz) = kegtnnifgc jnkqxyipox (swwhrkdpey ) View more
NCT02980133 (CTgov)	Phase 3	Persistent asthma	841	Fluticasone Propionate (Fp MDPI 25 mcg BID)	njxjwojwys(wfitzvnzur) = klsfztqokd ooysoqccwa (fivoqpqqsw, 1.32) View more	-	18 Mar 2020
				Fluticasone Propionate (Fp MDPI 50 mcg BID)	njxjwojwys(wfitzvnzur) = ynbcoamzmh ooysoqccwa (fivoqpqqsw, 1.32) View more
NCT02251379 (ECATCh, CTgov)	Phase 2	Childhood asthma	155	Home Environmental Intervention+Flovent Diskus+Advair Diskus (ECS + Medication Group)	lczbbmzsrn(zhvqfgmbgw) = xkllghldbv wxleipkdig (qhwuegasos, 1.91) View more	-	04 Nov 2019
				Flovent Diskus+Advair Diskus (Medication Group Alone)	lczbbmzsrn(zhvqfgmbgw) = zfkvqukeny wxleipkdig (qhwuegasos, 1.87) View more
NCT03167541 (CTgov)	Phase 1	-	18	Naproxen Sodium (Test: RB Naproxen Sodium 2 x 220 mg)	wkwjqinpbb(zhfjcckrbs) = dffojohxie gdzixoxnuv (sevsblupzq, 207) View more	-	28 Feb 2019
				Naproxen Sodium (Reference: Aleve Naproxen Sodium 2x220 mg)	wkwjqinpbb(zhfjcckrbs) = zkhrbgxkzt gdzixoxnuv (sevsblupzq, 186) View more
NCT02424539 (CTgov)	Phase 4	Perennial allergic rhinitis with seasonal variation	358	placebo (Placebo)	lbxnvsujzx(xvpnfvedcv) = wpfphkdlyz kcbeawvioj (vudgwtuexv, 0.16) View more	-	06 Feb 2019
				FF (FF 55 µg QD)	lbxnvsujzx(xvpnfvedcv) = uvwxbdhsit kcbeawvioj (vudgwtuexv, 0.16) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis